anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Radical prostatectomy versus deferred treatment for localised prostate cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Prostate Cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
Telephone interventions for symptom management in adults with cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Cancer
Provide patient population that should be included in the study
Surgery versus radical endotherapies for early cancer and high‐grade dysplasia in Barrett's oesophagus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Barretts Oesophagus With High Grade Dysplasia 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
External beam radiation dose escalation for high grade glioma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. High Grade Glioma 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Physical activity interventions for disease‐related physical and mental health during and following treatment in people with non‐advanced colorectal cancer
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Adjuvant Therapy 4. Surgery 5. Young Adult 19-24 years 6. Colorectal Cancer 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for the management of malignant pleural effusions: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Malignant pleural effusion 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer
1. Aged 80 and over 80+ years 2. Endometrial Cancer 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Suspicious 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer
1. Hormone Receptor Positive Malignant Neoplasm Of Breast 2. Premenopausal State
Provide patient population that should be included in the study
Drugs for preventing lung cancer in healthy people
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Healthy
Provide patient population that should be included in the study
Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Breast Cancer Female 4. Middle Aged 45-64 years 5. Progesterone Receptor Positive Tumor 6. Young Adult 19-24 years 7. Estrogen Receptor Positive Tumor 8. Musculoskeletal Symptom 9. Aged 65-79 years
Provide patient population that should be included in the study
Hormone replacement therapy after surgery for epithelial ovarian cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Ovarian epithelial cancer 8. Surgery 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Drug therapy for delirium in terminally ill adults
1. Aged 80 and over 80+ years 2. Terminal Illness 3. Delirium 4. Adult 19-44 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Different infusion durations for preventing platinum‐induced hearing loss in children with cancer
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Adolescent 13-18 years 6. Cancer
Provide patient population that should be included in the study
Early versus delayed postoperative radiotherapy for treatment of low‐grade gliomas
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Low Grade Glioma Of Brain 8. Surgery 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Non-small cell lung cancer 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Urothelial Carcinoma 5. Invasive Bladder Cancer
Provide patient population that should be included in the study
Interval brain imaging for adults with cerebral glioma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Malignant Glioma Of Cerebrum
Provide patient population that should be included in the study
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. HIV infection 10. Aged 65-79 years 11. Healthy 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Cancer
Provide patient population that should be included in the study
Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Operation On Breast 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Breast Cancer 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Follow‐up strategies for patients treated for non‐metastatic colorectal cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Colorectal Cancer 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Chemotherapy 10. Middle Aged 45-64 years 11. Procedure On Colon 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Taxanes for adjuvant treatment of early breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Breast Cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
Hypofractionation for clinically localized prostate cancer
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Prostate Cancer
Provide patient population that should be included in the study
Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Abdominal surgery 4. Adult 19-44 years 5. Child 6-12 years 6. Procedure On Pelvis 7. Middle Aged 45-64 years 8. Infant 1 to 23 mo 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Long‐term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Glioma 5. Young Adult 19-24 years 6. Late Effect Of Injury 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of hospital stay and postoperative complications
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Disorder Of Digestive System 4. Gastrointestinal Surgery 5. Young Adult 19-24 years 6. Inflammatory Bowel Disease
Provide patient population that should be included in the study
Psychosocial interventions for informal caregivers of people living with cancer
1. Aged 80 and over 80+ years 2. Monitoring Of Patient With Cancer 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Caregiver 7. Patient care 8. Aged 65-79 years 9. Cancer
Provide patient population that should be included in the study
Exercise training undertaken by people within 12 months of lung resection for non‐small cell lung cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Non-small cell lung cancer 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hormone-dependent prostate cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
Perioperative nutrition for the treatment of bladder cancer by radical cystectomy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Radical Cystectomy 5. Young Adult 19-24 years 6. Bladder Cancer 7. Aged 65-79 years
Provide patient population that should be included in the study
Single‐dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Bladder Cancer 6. Urothelial Carcinoma 7. Aged 65-79 years
Provide patient population that should be included in the study
Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Radical Cystectomy 5. Young Adult 19-24 years 6. Bladder Cancer 7. Urothelial Carcinoma 8. Aged 65-79 years
Provide patient population that should be included in the study
Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Adolescent 13-18 years 6. Cancer
Provide patient population that should be included in the study
Risk‐reducing medications for primary breast cancer: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Neuroblastoma 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Robotic versus open radical cystectomy for bladder cancer in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Bladder Cancer
Provide patient population that should be included in the study
Mindfulness‐based stress reduction for women diagnosed with breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Early Breast Cancer 6. Metastatic breast cancer 7. Breast Cancer 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Systematic screening and assessment of psychosocial well‐being and care needs of people with cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Cancer
Provide patient population that should be included in the study
Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Febrile Neutropenia 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Cancer
Provide patient population that should be included in the study
Palliative interventions for controlling vaginal bleeding in advanced cervical cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Cervical Cancer 5. Vaginal Bleeding 6. Young Adult 19-24 years 7. Palliative Care 8. Advanced Cancer 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychological interventions for parents of children and adolescents with chronic illness
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Parent 5. Young Adult 19-24 years 6. Caregiver 7. Aged 65-79 years
Provide patient population that should be included in the study
Intralesional treatment versus wide resection for central low‐grade chondrosarcoma of the long bones
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Chondrosarcoma Of Bone
Provide patient population that should be included in the study
Non‐invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Lung Excision 5. Lung cancer 6. Young Adult 19-24 years 7. Aged 65-79 years
Provide patient population that should be included in the study
Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure in premenopausal women
1. Adult 19-44 years 2. Chemotherapy 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Ovarian Failure 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Dyspnea 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Cancer
Provide patient population that should be included in the study
Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Infant 1 to 23 mo 5. Young Adult 19-24 years 6. Birth to 1 mo 7. Breast Cancer 8. Aged 65-79 years
Provide patient population that should be included in the study
Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hepatocellular carcinoma 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa)
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Radical Hysterectomy 4. Middle Aged 45-64 years 5. Cervical Cancer 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
De‐intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV‐positive oropharyngeal carcinoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Human Papilloma Virus Infection 10. Aged 65-79 years 11. Squamous Cell Carcinoma Of Oropharynx 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise interventions for people undergoing multimodal cancer treatment that includes surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Surgery 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Cancer
Provide patient population that should be included in the study
Anti‐angiogenic therapy for high‐grade glioma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Glioma 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Metastatic Colorectal Cancer 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Radiotherapy 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Chemotherapy 10. Middle Aged 45-64 years 11. Young Adult 19-24 years 12. Birth to 1 mo 13. Cancer
Provide patient population that should be included in the study
Laparoscopy versus laparotomy for the management of early stage endometrial cancer
1. Aged 80 and over 80+ years 2. Endometrial Cancer 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Surgery 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Extended‐field radiotherapy for locally advanced cervical cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Cervical Cancer 5. Young Adult 19-24 years 6. Advanced Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hormone-dependent prostate cancer 6. Prostate Cancer Metastatic 7. Aged 65-79 years
Provide patient population that should be included in the study
Epidermal growth factor receptor blockers for the treatment of ovarian cancer
1. Aged 80 and over 80+ years 2. Ovarian Cancer 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise for reducing falls in people living with and beyond cancer
1. Aged 80 and over 80+ years 2. Falls 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Cancer
Provide patient population that should be included in the study
Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Cervical Cancer 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Rectal neoplasm 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Vomiting 5. Young Adult 19-24 years 6. Nausea 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Cancer
Provide patient population that should be included in the study
Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Chemotherapy 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Radiotherapy 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Cancer
Provide patient population that should be included in the study
Immunonutrition for patients undergoing surgery for head and neck cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Head and Neck Therapeutic Procedures 6. Head And Neck Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Brca1 Gene Mutation Positive 6. Brca2 Gene Mutation Positive 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis
1. Aged 80 and over 80+ years 2. Brain Metastasis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Virtual reality simulation training for health professions trainees in gastrointestinal endoscopy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare Professional 4. Young Adult 19-24 years 5. Student
Provide patient population that should be included in the study
Home parenteral nutrition for people with inoperable malignant bowel obstruction
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Cancer 8. Intestinal Obstruction 9. Parenteral Nutrient
Provide patient population that should be included in the study
Communication skills training for healthcare professionals working with people who have cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Cancer
Provide patient population that should be included in the study
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Metastatic Disease 6. Advanced Cancer 7. Urothelial Carcinoma 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Adult 19-44 years 11. Chemotherapy 12. Middle Aged 45-64 years 13. Young Adult 19-24 years 14. Birth to 1 mo
Provide patient population that should be included in the study
Anticoagulation for perioperative thromboprophylaxis in people with cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Surgery 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Cancer
Provide patient population that should be included in the study
Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Necrosis Due To Ionizing Radiation 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Brain neoplasm 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Anticoagulation for people with cancer and central venous catheters
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Central Venous Catheterisation 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Cancer
Provide patient population that should be included in the study
Primary cryotherapy for localised or locally advanced prostate cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Prostate Cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Malignant gastrointestinal obstruction 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Hormone replacement therapy for women previously treated for endometrial cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Endometrial Cancer 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Sexually Active 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Currently Not Sexually Active 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Hyperbaric oxygenation for tumour sensitisation to radiotherapy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Solid Tumor 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Radiotherapy 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Neoplasm Of Biliary Tract 6. Aged 65-79 years
Provide patient population that should be included in the study
Breast surgery for metastatic breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Metastatic breast cancer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral water soluble contrast for malignant bowel obstruction
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Neoplasm Of Intra-abdominal Organs 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Intestinal Obstruction
Provide patient population that should be included in the study
Ghrelin for the management of cachexia associated with cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cachexia 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Cancer
Provide patient population that should be included in the study
Non‐steroidal anti‐inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Cervical Intraepithelial Neoplasia Grade 1 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Influenza vaccines in immunosuppressed adults with cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Cancer
Provide patient population that should be included in the study
Physical activity for women with breast cancer after adjuvant therapy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Chemotherapy 4. Middle Aged 45-64 years 5. Adjuvant Therapy 6. Young Adult 19-24 years 7. Radiotherapy 8. Breast Cancer 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Selenium for preventing cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Cancer 8. Selenium Measurement
Provide patient population that should be included in the study
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
1. Aged 80 and over 80+ years 2. Brain Metastasis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Radiotherapy 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pelvic Neoplasm 6. Radiotherapy 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Gefitinib for advanced non‐small cell lung cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Non-small cell lung cancer 6. Aged 65-79 years
Provide patient population that should be included in the study
Bisphosphonates for advanced prostate cancer
1. Aged 80 and over 80+ years 2. Primary Malignant Neoplasm Of Prostate Metastatic To Bone 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Tumour bed boost radiotherapy for women after breast‐conserving surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Breast Conserving Surgery 5. Young Adult 19-24 years 6. Breast Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Closure methods for laparotomy incisions for preventing incisional hernias and other wound complications
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Laparotomy 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Bisphosphonates and other bone agents for breast cancer
1. Aged 80 and over 80+ years 2. Advanced Breast Cancer 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Secondary malignant neoplasm of bone 7. Early Breast Cancer 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Lymphadenectomy for the management of endometrial cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Neoplasm Of Endometrium 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases
1. Aged 80 and over 80+ years 2. Brain Metastasis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pancreaticoduodenectomy 6. Aged 65-79 years
Provide patient population that should be included in the study
Intravesical electromotive drug administration for non‐muscle invasive bladder cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Invasive Bladder Cancer 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Laparoscopic and robotic‐assisted versus open radical prostatectomy for the treatment of localised prostate cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Prostate Cancer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Parenteral anticoagulation in ambulatory patients with cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Anticoagulant therapy 11. Adolescent 13-18 years 12. Cancer
Provide patient population that should be included in the study
Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Hydatidiform Mole 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Neuroblastoma 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Home‐based multidimensional survivorship programmes for breast cancer survivors
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Breast Carcinoma Stage I 5. Young Adult 19-24 years 6. Carcinoma Breast Stage III 7. Breast Carcinoma Stage II 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Nonmetastatic cancer 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Procarbazine, lomustine and vincristine for recurrent high‐grade glioma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. High Grade Glioma 5. Young Adult 19-24 years 6. Recurrent Disease 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐steroidal anti‐inflammatory drugs (NSAIDs) for cancer‐related pain in children and adolescents
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Cancer Pain 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Opioids for cancer‐related pain in children and adolescents
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Cancer Pain 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychosocial interventions for fatigue during cancer treatment with palliative intent
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Fatigue 6. Advanced Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cancer Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral paracetamol (acetaminophen) for cancer pain
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cancer Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery)
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Vomiting 5. Young Adult 19-24 years 6. Nausea 7. Advanced Cancer 8. Aged 65-79 years
Provide patient population that should be included in the study
Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in women with gynaecological malignancies
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Cancer 8. Pelvic Lymphadenectomy
Provide patient population that should be included in the study
Ketamine as an adjuvant to opioids for cancer pain
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cancer Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Metastatic Colorectal Cancer 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Platinum‐containing regimens for metastatic breast cancer
1. Aged 80 and over 80+ years 2. Advanced Breast Cancer 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Early palliative care for adults with advanced cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Advanced Cancer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Focal laser treatment in addition to chemotherapy for retinoblastoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Retinoblastoma 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients with cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Infection 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Febrile Neutropenia 8. Young Adult 19-24 years 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Cancer
Provide patient population that should be included in the study
Drug therapy for symptoms associated with anxiety in adult palliative care patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Palliative Care 6. Anxiety 7. Generalized Anxiety Disorder 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Tramadol with or without paracetamol (acetaminophen) for cancer pain
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Cancer Pain 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Immunotherapy for metastatic renal cell carcinoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Metastatic Renal Cell Carcinoma 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Partial nephrectomy versus radical nephrectomy for clinical localised renal masses
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Renal cell carcinoma 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Alvimopan for recovery of bowel function after radical cystectomy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Bladder Cancer 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Middle Aged 45-64 years 10. Radical Cystectomy 11. Young Adult 19-24 years 12. Birth to 1 mo 13. Hemorrhagic Cystitis
Provide patient population that should be included in the study
Biopsy versus resection for the management of low‐grade gliomas
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Glioma 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Sarcoma Of Soft Tissue 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Online support groups for women with breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Breast Cancer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating non‐muscle‐invasive bladder cancer
1. Superficial Bladder Cancer 2. Transurethral resection of bladder tumour 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Carcinoma In Situ Of Bladder
Provide patient population that should be included in the study
External beam radiotherapy for unresectable hepatocellular carcinoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hepatocellular carcinoma 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for raising breast cancer awareness in women
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Breast Cancer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Methadone for cancer pain
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Cancer Pain 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Second‐line systemic therapy for metastatic colorectal cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Metastatic Colorectal Cancer 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Colorectal Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Abnormal Cervical Cytology 6. Aged 65-79 years
Provide patient population that should be included in the study
Antibiotics for infection prevention after excision of the cervical transformation zone
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Large Loop Excision Of Transformation Zone 5. Needle Excision of the Transformation Zone 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Cervical Intraepithelial Neoplasia 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Dietary fibre for the prevention of recurrent colorectal adenomas and carcinomas
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Colon Adenomatous Polyp 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Axillary treatment for operable primary breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Breast Cancer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Fulvestrant for hormone‐sensitive metastatic breast cancer
1. Aged 80 and over 80+ years 2. Advanced Breast Cancer 3. Middle Aged 45-64 years 4. Metastatic breast cancer 5. Postmenopausal 6. Aged 65-79 years
Provide patient population that should be included in the study
Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women diagnosed with breast cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Metastatic breast cancer 6. Breast Cancer 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small‐volume primary oropharyngeal carcinoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Oropharyngeal Cancer 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Nipple‐ and areola‐sparing mastectomy for the treatment of breast cancer
1. Aged 80 and over 80+ years 2. Invasive breast cancer 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Ductal Carcinoma In Situ 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Educational interventions for the management of cancer‐related fatigue in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Fatigue 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Cancer
Provide patient population that should be included in the study
Adjuvant platinum‐based chemotherapy for early stage cervical cancer
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Cervical Cancer 5. Surgery 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years